Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs to treat chronic inflammatory diseases.
In recent years Kither has focused its first line of activities on the development of a small peptide (KIT-2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT-2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT-2014 compound is currently undergoing the pre-clinical phase of clinical development.
Kither’s product portfolio also includes a molecule (KIT-CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the KIT-CL27 molecule.